Select your country
Select a country to go to the website of the respective STADA sales company.
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
At least 2.2 billion people worldwide live with some form of vision impairment, ranging from the mild to the severe. According to the World Health Organization, more than half of these people have been unable to get, the care they need for conditions like short and far sightedness, glaucoma and cataracts.
STADA is deeply committed to making Specialty treatments for serious eye conditions available to as many people as possible.
STADA has already secured approval in the European Union and the UK for a biosimilar medicine which is authorized for use in diseases including wet age-related macular degeneration and diabetic macular oedema. This cost-effective medicine was co-developed by STADA and one of its strategic partners, representing STADA’s first biologic development program and first biologic asset in opthalmalogy.